NICE recommends vortioxetine
The National Institute for Health and Care Excellence (NICE) has published final guidance that recommends vortioxetine (Brintellix; Lundbeck, Takeda) as third-line treatment for major depressive episodes. Vortioxetine should be considered as a treatment option for adults whose condition has responded inadequately to two antidepressants within the current episode.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200190
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com